UPDATE -- Intellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, announced that two scientific abstracts have been accepted for presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 16-19, 2018, in Chicago. The first presentation will share information relating to Intellia’s lead in vivo program, for transthyretin amyloidosis. The data being presented include results from an ongoing collaboration with researchers at the University of Porto in Portugal. The second presentation will focus on Intellia’s ongoing research collaboration with IRCCS Ospedale San Raffaele in Italy to develop CRISPR-edited, T-cell therapies to address hard-to-treat cancers. Intellia will also participate in an education session on RNA therapeutics. Details of Intellia’s presentations are as follows: “Re
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- 2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]Yahoo! Finance
- Rob Lauzon's Top Picks: March 25, 2024 [BNN Bloomberg (Canada)]BNN Bloomberg
- Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/22/24 - Beat
NTLA
Sec Filings
- 4/16/24 - Form PRE
- 4/15/24 - Form 8-K
- 3/22/24 - Form 8-K
- NTLA's page on the SEC website